REGISTER
The ongoing challenge of CNS progression in ALK-positive NSCLC
Prof. Liu discussed the ongoing challenge of CNS progression in ALK-positive NSCLC, including how to optimize systemic TKI therapy plus local intervention and how to interpret the long-term value of first-line lorlatinib.

Prof. Geoffrey Liu, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada

Host:Prof. Ming Gao, The First Affiliated Hospital of Zhengzhou University, China


Prof. Liu discussed the ongoing challenge of CNS progression in ALK-positive NSCLC, including how to optimize systemic TKI therapy plus local intervention and how to interpret the long-term value of first-line lorlatinib. He also shared his perspectives on treatment sequencing, patient preferences, and future directions in ALK research.

0
0
Loading